Moxaverine

Structural formula
General
Non-proprietary name	Moxaverine
other names	1-Benzyl-3-ethyl-6,7-dimethoxy-isoquinoline ( IUPAC ) Eupaverine
Molecular formula	C 20 H 21 NO 2
External identifiers / databases
CAS number 10539-19-2 EC number 234-117-5 ECHA InfoCard 100.031.003 PubChem 70882 ChemSpider 64045 DrugBank DB12251 Wikidata Q425881
Drug information
ATC code	A03 AD30 C04 AX42
Drug class	Antispasmodic peripheral vasodilator
properties
Molar mass	307.39 g · mol -1
safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed GHS hazard labeling no classification available
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

The drug moxaverine ( eupaverine ) is a musculotropic spasmolytic (antispasmodic agent that acts on the so-called smooth muscles ) and a peripheral vasodilator (active ingredient that dilates blood vessels).

From a chemical point of view, it is a derivative of isoquinoline .

application areas

Moxaverine can be used to treat spasmodic complaints in the gastrointestinal tract , the gallbladder / biliary tract , the lower urinary tract and the bronchi , whereby it suppresses contractions of the smooth muscles.

In Germany it is currently marketed in the form of its hydrochloride against circulatory disorders of the arteries (e.g. in arteriosclerosis or myocardial infarction ), whereby it has a peripheral vasodilator (vasodilator) effect.

Pharmacological properties

Moxaverine is - like the similarly acting alkaloid papaverine (from which it is derived) - a cAMP - phosphodiesterase inhibitor , which is responsible for the vasodilatory effect.

literature

• C.-J. Estler (Ed.): Pharmacology and Toxicology . 4th edition Schattauer, Stuttgart a. New York 1995. pp. 89-90.
• R. Mannhold: Inhibition of calmodulin dependent c-AMP-phosphodiesterase by moxaverine and papaverine . In: Arzneimittelforschung , Vol. 38/12, 1988, pp. 1806-1808. PMID 2854468 .

Individual evidence

1. ↑ Walter Schunack: Medicines. Springer-Verlag, 2013, ISBN 978-3-663-14234-8 , p. 94 ( limited preview in the Google book search).
2. ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

Trade names

Collateral forte (D)

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !